Akeso: We’re The Leaders In Bispecific Cancer Immunotherapies

 
• By Andrew McConaghie
  
The Shenzhen middle channel bridge in the Pearl river delta connects the cities of Shenzen and Zhongshan, where Akeso is headquartered. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas